Premium
Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation
Author(s) -
Sánchez Quintana Ana,
Rull Pablo Ríos,
Atienza Joaquín Breña,
McDonnell Cristiotario
Publication year - 2013
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12116
Subject(s) - medicine , lenalidomide , dyscrasia , autologous stem cell transplantation , transplantation , stem cell , plasma cell , plasma cell dyscrasia , oncology , surgery , immunology , multiple myeloma , antibody , immunoglobulin light chain , biology , genetics
Plasma cell dyscrasias ( PCD ) are a spectrum of diseases characterized by clonal proliferation of plasma cells secreting a monoclonal immunoglobulin. Although considered an incurable disease, a combination of autologous stem cell transplant with novel therapies, including lenalidomide, has improved the overall and progression‐free survival of these patients. Renal impairment is an important complication of the disease that, in some cases, progresses to end‐stage renal disease. Due to the characteristics of PCD , traditionally these patients have not been candidates for renal transplantation. However, treatment improvement allows a reconsideration of this perception, especially in younger patients with good performance status and treatment response. We report two cases of patients diagnosed with PCD undergoing renal transplantation after autologous stem cell transplantation, both cases under treatment with lenalidomide. We also report their perioperative management and their outcome.